[Bio Peptide Co](/)

From the body [GLP-1](/glp-1#origin-glp1) [GHRH](/ghrh#origin-ghrh) [The thymus](/signal-families#origin-thymus)

[Overview](/)

Into adaptations [Semaglutide](/glp-1#adaptation-glp1) [Sermorelin & tesamorelin](/ghrh#adaptation-ghrh) [PT-141](/signal-families#adaptation-alpha-msh)

[The seven families](/)

The reading beside the relationships

# The reading beside the relationships

Here’s the reading behind the chapters. Each linked title opens a source; the note explains why it’s here. Follow the part you’re curious about. Nobody needs to read the whole shelf in one sitting.

## [The semaglutide label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)

Wegovy (semaglutide) uses and warnings. The label defines what the approval covers, including who it’s for.

## [Semaglutide safety in people](https://pubmed.ncbi.nlm.nih.gov/34305810/)

A review of side effects, from common stomach trouble to gallbladder concerns and pancreatitis warnings.

## [A weight-management trial](https://pubmed.ncbi.nlm.nih.gov/33567185/)

A maker-funded trial in adults without diabetes compared semaglutide with placebo, with lifestyle support in both groups. Results are averages.

## [How long semaglutide stays around](https://pubmed.ncbi.nlm.nih.gov/38952487/)

Why semaglutide lasts longer than natural GLP-1, and how the body handles the medicine.

## [The GHRH family](https://pubmed.ncbi.nlm.nih.gov/39537825/)

The natural GHRH message and its relatives. A shared receptor doesn’t give them identical benefits.

## [The FDA record on discontinued sermorelin](https://www.federalregister.gov/d/2013-04827)

FDA’s finding about discontinued Geref (sermorelin). It doesn’t approve today’s compounded preparations.

## [Sermorelin’s earlier clinical setting](https://pubmed.ncbi.nlm.nih.gov/18031173/)

Earlier sermorelin studies, mostly in children with growth hormone deficiency, including the side effects reported.

## [The tesamorelin label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75)

Tesamorelin’s HIV-associated use and cautions. The label also rules out general weight-loss management.

## [The bremelanotide label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9)

Bremelanotide’s approved low-desire condition and population, alongside its blood-pressure and cardiovascular restrictions.

## [Bremelanotide in controlled trials](https://pubmed.ncbi.nlm.nih.gov/31599840/)

Bremelanotide trials in premenopausal women with a defined low-desire disorder. Results concern average changes in desire and related distress compared with placebo.

## [A second look at the bremelanotide trials](https://pubmed.ncbi.nlm.nih.gov/33678061/)

A re-analysis found small effects on desire and distress and questioned how much difference those changes made in everyday life.

## [Thymosin alpha-1’s isolation](https://pubmed.ncbi.nlm.nih.gov/265536/)

The isolation and sequence work on thymosin alpha-1. Finding a peptide doesn’t establish a treatment.

## [A larger sepsis trial](https://pubmed.ncbi.nlm.nih.gov/39814420/)

A maker-funded sepsis trial found no clear difference in deaths over 28 days compared with placebo.

## [FDA’s thymosin alpha-1 review](https://www.fda.gov/media/183892/download)

FDA’s thymosin alpha-1 review, including evidence and quality concerns. A review isn’t an approval.

## [Kisspeptin’s clinical research](https://pubmed.ncbi.nlm.nih.gov/38265397/)

Clinical research on kisspeptin. It describes investigational uses, rather than an approved treatment.

## [The BPC-157 evidence gap](https://pubmed.ncbi.nlm.nih.gov/40789979/)

Mostly animal research, with very limited human evidence. Healing claims and long-term safety remain unresolved.

## [GHK and copper](https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/)

Natural GHK and its copper-bound form. This review explains the relationship behind the names.

## [Collagen production in cell cultures](https://pubmed.ncbi.nlm.nih.gov/3169264/)

Collagen production in cells grown in a lab. This wasn’t a test of injections in people.

## [FDA’s peptide safety entries](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks)

FDA’s page, current as of April 22, 2026. Withdrawn requests aren’t clearance or approval for compounding.

## [Compounding and approval](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)

FDA explains why compounded preparations aren’t FDA-approved, even when they share an ingredient with an approved medicine.

## [How cosmetic oversight differs](https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated)

Cosmetic oversight differs from drug approval. A skincare context doesn’t establish injection safety.

We follow the body’s messages here as a guide; Bio Peptide Co is not a clinic, pharmacy or seller.

[References](/references) [About the guide](/about) [Contact](/contact) [Read in Markdown](/index.md)

© 2026 Bio Peptide Co